<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01844245</url>
  </required_header>
  <id_info>
    <org_study_id>EHBH B-RFA 2013-001</org_study_id>
    <nct_id>NCT01844245</nct_id>
  </id_info>
  <brief_title>Endobiliary RFA for Unresectable Malignant Biliary Strictures</brief_title>
  <official_title>Endoscopic Radiofrequency Ablation for Malignant Biliary Strictures Due to Unresectable Cholangiocarcinoma or Ampullary Carcinoma: a Randomised, Controlled, Multicentre Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bing Hu</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eastern Hepatobiliary Surgery Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Only a small proportion of patients with cholangiocarcinoma or ampullary carcinoma are&#xD;
      suitable for surgical resection. The endoscopic or percutaneous transhepatic biliary drainage&#xD;
      is accepted approaches for the relief of jaundice in malignant biliary obstruction. But&#xD;
      restoration of bile flow have few improvement of the survival of cancer patient. By using&#xD;
      endobiliary radiofrequency energy to destruct the tumorous tissue may delay tumour growth,&#xD;
      which might improve the survival of patients. The feasibility and safety of this technique&#xD;
      using HabibTM EndoHBP probe has been evident. The aims of this randomised, controlled,&#xD;
      multicentre study is to evaluate whether endobiliary radiofrequency ablation(RFA) can improve&#xD;
      the median survival of patients with unresectable biliary malignancy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      RFA is well established method for treatment of some solid tumors, like liver cancer, lung&#xD;
      cancer, etc. Recently, an endoscopically applicable radiofrequency probe, HabibTM EndoHBP&#xD;
      catheter, was approved for clinical use. It uses bipolar electrical energy for tissue&#xD;
      coagulation and can be easily applied during endoscopic retrograde cholangiopancreatography&#xD;
      (ERCP). Endobiliary radiofrequency can destruct the tumor tissue and has potential benefit&#xD;
      for controlling tumour growth. Several cohort studies have been published and the feasibility&#xD;
      and safety of such technique has been proved.&#xD;
&#xD;
      The aims of this study is to conduct a randomised, controlled, multicentre clinical trial to&#xD;
      compare the effect of endobiliary RFA plus biliary stenting with only biliary stenting in&#xD;
      patients with unresectable cholangiocarcinoma or ampullary carcinoma.&#xD;
&#xD;
      The objectives are&#xD;
&#xD;
        -  To evaluate whether endobiliary RFA prior to biliary stenting can improve the patients'&#xD;
           survival as compared to the only stenting therapy.&#xD;
&#xD;
        -  To assess the impact of RFA on the stent's patency.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2013</start_date>
  <completion_date type="Actual">July 2019</completion_date>
  <primary_completion_date type="Actual">December 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall survival</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Patency of stents</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Unscheduled readmission rates</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serious adverse events</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">174</enrollment>
  <condition>Cholangiocarcinoma</condition>
  <condition>Ampullary Carcinoma</condition>
  <arm_group>
    <arm_group_label>Endobiliary RFA group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Endoscopic retrograde cholangiopancreatography (ERCP) would be performed under standard operating conditions to confirm the biliary malignancy. Subjects will receive endobiliary radiofrequency ablation (Endobiliary RFA) followed by plastic stent(s) placement.&#xD;
Three months later, subjects will receive the second RFA therapy followed by biliary stents (plastic or SEMS) placement.&#xD;
During follow-up, if stent occlusion occurs, the patient will undergo endoscopic re-intervention for stent exchange without endobiliary RFA</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Endoscopic retrograde cholangiopancreatography (ERCP) would be performed under standard operating conditions to confirm the biliary malignancy. Subjects will receive plastic biliary stent(s) placement only.&#xD;
Three months later, subjects will receive the second endoscopic intervention for stents (plastic or SEMS) exchange.&#xD;
During follow-up, if stent occlusion occurs, the patient will undergo endoscopic re-intervention for stent exchange without endobiliary RFA</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Radiofrequency ablation (RFA)</intervention_name>
    <description>The RFA probe is introduced into bile duct. Bipolar electronic coagulation is performed to the tumorous segment.</description>
    <arm_group_label>Endobiliary RFA group</arm_group_label>
    <other_name>Endobiliary RFA</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Either gender greater than or equal to 18 years of age.&#xD;
&#xD;
          -  Cholangiocarcinoma or ampullary cancer unsuitable for surgical resection by staging,&#xD;
             comorbidities or patient wishes. Criteria of unresectability being based on 1)&#xD;
             metastatic disease or 2) locally advanced.&#xD;
&#xD;
          -  Biliary obstruction, Bilirubin &gt; 40umol/L at diagnosis&#xD;
&#xD;
          -  Subjects capable of giving informed consent&#xD;
&#xD;
          -  Life expectancy of at least 3 months&#xD;
&#xD;
          -  Histologically (preferred) or radiologically confirmed cholangiocarcinoma or ampullary&#xD;
             cancer&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Cardiac Pacemaker&#xD;
&#xD;
          -  Patient unstable for endoscopy&#xD;
&#xD;
          -  Inability to give informed consent&#xD;
&#xD;
          -  Coagulopathy (INR &gt; 2.0 or PTT &gt; 100 sec or platelet count &lt; 50,000)&#xD;
&#xD;
          -  Performance status ECOG â‰¥3 (confined to bed / chair &gt; 50% waking hours)&#xD;
&#xD;
          -  Active suppurative cholangitis&#xD;
&#xD;
          -  Complex stenoses will not be eligible for the trial&#xD;
&#xD;
          -  Patients without access to duodenum or ampulla are not candidates for ERCP and&#xD;
             stenting&#xD;
&#xD;
          -  Malignant ascites&#xD;
&#xD;
          -  Presence of main portal vein thrombosis&#xD;
&#xD;
          -  Prior stents placement&#xD;
&#xD;
          -  Prior Billroth II or roux-en Y reconstruction&#xD;
&#xD;
          -  Inability to insert a guide wire across the malignant stricture&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Presence of other malignancy&#xD;
&#xD;
          -  Life expectancy &lt; 3months&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bing Hu, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Eastern Hepatobiliary Surgery Hospital, The Second Military Medical University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Beijing Friendship Hospital Affiliated to Capital University of Medical Sciences</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100050</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Guangxi Medical University</name>
      <address>
        <city>Nanning</city>
        <state>Guangxi</state>
        <zip>530021</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The General Hospital of Shenyang Military Region</name>
      <address>
        <city>Shenyang</city>
        <state>Liaoning</state>
        <zip>110015</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eastern Hepatobiliary Surgery Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200438</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Xijing Hospital of the Forth Military Medical University</name>
      <address>
        <city>Xi'an</city>
        <state>Shanxi</state>
        <zip>710032</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hangzhou First People's Hospital</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310006</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>April 28, 2013</study_first_submitted>
  <study_first_submitted_qc>April 30, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 1, 2013</study_first_posted>
  <last_update_submitted>October 9, 2020</last_update_submitted>
  <last_update_submitted_qc>October 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 14, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Eastern Hepatobiliary Surgery Hospital</investigator_affiliation>
    <investigator_full_name>Bing Hu</investigator_full_name>
    <investigator_title>Professor, Head of Endoscopy Center</investigator_title>
  </responsible_party>
  <keyword>Cholangiocarcinoma</keyword>
  <keyword>Ampullary carcinoma</keyword>
  <keyword>Endoscopic retrograde cholangiopancreatography</keyword>
  <keyword>Radiofrequency ablation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Cholangiocarcinoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

